WHO Approves First Malaria Drug for Infants in Global Health Milestone
The World Health Organization has granted prequalification to Coartem Baby, the first malaria treatment specifically approved for newborns and young infants. The approval addresses a longstanding gap in treatment options, as up to 18% of children under six months in parts of Africa contract malaria but previously had no safe dedicated medication. Malaria caused approximately 610,000 deaths in 2024, with roughly three-quarters occurring among children under five in Africa.
Progressive outlets frame this as a landmark global health equity achievement, highlighting the disproportionate burden malaria places on vulnerable populations in low-income African nations and the urgent need for international health investment.
The WHO has formally prequalified Coartem Baby, enabling its widespread distribution as the first malaria treatment approved specifically for infants, targeting a population segment that accounts for a significant share of the disease's global death toll.
Conservative outlets may highlight the role of pharmaceutical development and regulatory processes in producing this breakthrough, pointing to the approval as a success of structured drug development and WHO's technical prequalification system.
The WHO has formally prequalified Coartem Baby, enabling its widespread distribution as the first malaria treatment approved specifically for infants, targeting a population segment that accounts for a significant share of the disease's global death toll.
WHO prequalification of Coartem Baby marks the first approved malaria treatment for newborns, a group previously excluded from safe pharmacological options.